

BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE-CELL LYMPHOMA IN LATIN AMERICA

LINFOMA ANAPLÁSICO DE CÉLULAS GRANDES ASOCIADO A IMPLANTES MAMARIOS EN LATINOAMÉRICA

Gianella F. Ugarte ^{1,a}, Carlos Noriega-Baella  ^{1,b}

Dear Editor:

After reading the 2023 publication by Manjarres A. et al. in your esteemed journal on cancer and breast implants, I would like to contribute additional data regarding breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) in Latin America. This work highlights the lack of knowledge and evidence in Latin American countries, a crucial aspect given the classification of BIA-ALCL as a new pathological entity by the World Health Organization in 2016⁽¹⁾.

BIA-ALCL is a rare T-Cell Non-Hodgkin's lymphoma, uncommonly linked to an increased risk due to the use of breast implants, especially textured ones⁽²⁾. Additional factors, such as bacteria, chronic irritation, and genetic predisposition, have also been identified as contributors⁽³⁾.

Although breast implant registries have been established in various countries, like the PROFILE in the U.S.⁽⁴⁾, the incidence of BIA-ALCL remains limited. In Spain, there is also a breast implant registry called the Spanish Breast Implant Registry. From 1997 to 2018, significant studies on BIA-ALCL have been conducted, such as that by Miranda RN et al⁽⁵⁾.

According to the systematic review by Torres A et al., there were 118 cases, in which the majority were women, and 3% were men at birth. In 77% of the cases, race was not recorded: 19% were described as White, Caucasian, or European; 3% as Latino; and one case as African American. The highest prevalence was in the U.S. with 39%, followed by the United Kingdom and Spain; each with 9%. In Latin America, there were three cases in Brazil and one in Mexico⁽⁶⁾.

In 2020, the CDC issued a warning about implants, reflecting significant advancements in the medical literature. Despite this, more than 10 million people globally have textured implants⁽⁷⁾.

According to the study by the Ibero-Latin-American Federation of Plastic Surgery (FILACP, by its Spanish acronym) Implant Registry Committee, there is evidence of a transition to smooth breast implants instead of textured ones among Latin American plastic surgeons. The proportion of textured implants decreased from 85.1% in 2016 to 53.8% in 2020, while smooth ones increased from 12.7% in 2016 to 42% in 2020. This possibly relates to concerns about the risk of BIA-ALCL. As of April 2020, 106 cases of BIA-ALCL were registered in nine countries of the FILACP: Argentina, Chile, Colombia, Spain, Mexico, Panama, Portugal, and Venezuela; Brazil was the most affected with 28 cases⁽⁸⁾.

¹ Instituto de Investigaciones en Ciencias Biomédicas. Faculty of Human Medicine, Universidad Ricardo Palma, Lima, Peru.

^a Medical Student.

^b Surgeon.

Cite as: F. Ugarte G, Noriega-Baella C. Breast Implant-Associated Anaplastic Large-Cell Lymphoma in Latin America. Rev Fac Med Hum. 2024;24(1):211-212. [doi10.25176/RFMH.v24i1.6425](https://doi.org/10.25176/RFMH.v24i1.6425)



Although it is a rare complication, it should be considered that in Latin America, particularly in Brazil, many breast augmentation surgeries are performed⁽⁹⁾. In Chile, cases have been reported suggesting that BIA-ALCL should be considered as a differential diagnosis in patients with periprosthetic seroma or capsular tumors; cytological study of the periprosthetic effusion is useful for an early diagnosis of BIA-ALCL⁽¹⁰⁾.

Moreover, in Panama, cases of BIA-ALCL have been documented in patients with textured prostheses, and a study in Mexico, with a population of 87 cases, found eight cases with textured breast implants, supporting the theory of its presence in Latin American countries⁽¹²⁾.

Authorship contribution: Gianella F. Ugarte participated in conceptualization, research, methodology, resources, and writing of the original draft. Carlos Noriega Baella participated in conceptualization, research, methodology, resources, and writing of the original draft.

Funding: Self-funded.

Correspondence: Gianella Fernanda Ugarte Farfán.

Address: Jirón Ismael Bielich 799, Dpto 40. Santiago de Surco, Lima, Perú.

Telephone: (+51) 943105400

E-mail: gianellaugarterefan@gmail.com

REFERENCES

1. Javier Gomepedroso Rea, Paola Iturralde Rosas Priego, Miguel Ángel Mancera Reséndiz, Daniela Stuht Lopez, Manuel Ubiergo García, Linfoma anaplásico de células grandes asociado a implantes mamarios. Una enfermedad rara y poco conocida. Revista de Senología y Patología Mamaria, Volume 35, Issue 2,2022,Pages 124-129,ISSN 0214-1582, Disponible en: <https://doi.org/10.1016/j.senol.2020.07.003>.
2. Wang Y, Zhang Q, Tan Y, Lv W, Zhao C, Xiong M, Hou K, Wu M, Ren Y, Zeng N, Wu Y. Current Progress in Breast Implant-Associated Anaplastic Large Cell Lymphoma. Front Oncol. 2022 Jan 6;11:785887. doi: [10.3389/fonc.2021.785887](https://doi.org/10.3389/fonc.2021.785887).
3. Ramos-Gallardo G, Cuena-Pardo J, Iribarren-Moreno R, et al. Análisis de una encuesta sobre la evolución y cambio en los implantes mamarios. Cir Plast. 2022;32(4):165-171. doi: [10.35366/108770](https://doi.org/10.35366/108770)
4. Colleen McCarthy, MD. PROFILE .The Plastic Surgery Foundation.2023. Disponible en: <https://www.thepsf.org/research/registries/profile>
5. Miranda RN, Medeiros LJ, Ferrufino-Schmidt MC, Keech JA Jr, Brody GS, de Jong D, Dogan A, Clemens MW. Pioneers of Breast Implant-Associated Anaplastic Large Cell Lymphoma: History from Case Report to Global Recognition. Plast Reconstr Surg. 2019 Mar;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):75-14S. doi: [10.1097/PRS.0000000000000564](https://doi.org/10.1097/PRS.0000000000000564)
6. Torres Pérez Asia, Gijón Vega María, Kenig Nitzan, Montón Echeverría Javier, Gómez Bajo Gregorio Jesús, Vaquero Pérez María del Mar. Linfoma anaplásico de células grandes e implantes mamarios: revisión sistemática de las casuísticas publicadas. Cir. plást. iberolatinoam. [Internet]. 2020 Mar ; 46(1): 25-36. Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0376-78922020000100005
7. Mehta-Shah N, Ghione P. An Updated Approach and Understanding of Breast Implant-Associated Anaplastic Large Cell Lymphoma. J Natl Compr Canc Netw. 2022 Mar;20(3):309-315. doi: [10.6004/jnccn.2022.7004](https://doi.org/10.6004/jnccn.2022.7004).
8. Sainz-Arregui José, Vaquero Pérez María del Mar. Tendencia en el uso de implantes mamarios de los cirujanos plásticos iberolatinoamericanos. Estudio FILACP 2010-2020. Cir. plást. iberolatinoam. [Internet]. 2020 Jun ; 46(2): 125-140. Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0376-78922020000300003
9. RECHIA GC, AITA VH. Desconforto mamário após mamoplastia de aumento: relato de caso. Rev Bras Cir Plást. [Internet]. 2021 Jul;36(3):334–8. Available from: <https://doi.org/10.5935/2177-1235.2021RBCP0102>
10. Misad S, Carlos, Walker B, Kenneth, Valbuena José R, Guerra S, Claudio, Camus A, Mauricio, Ocqueteau Mauricio et al . Linfoma anaplásico de células grandes asociado a implantes mamarios diagnosticado mediante punción por aguja fina. Caso clínico. Rev. méd. Chile [Internet]. 2020 Ago ; 148(8): 1207-1212. Disponible en: https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000801207
11. Picard-Ami Jr Luis A. Primer caso en Panamá de linfoma anaplásico de células grandes asociadas a implantes mamarios (LACG-AIM). cir. plástico. iberolatinoam. [Internet]. 2020 setiembre ; 46 (3) : 273 - 282 . Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0376-78922020000400004
12. Ramos-Gallardo GO, Carballo-Zarate AA, Cuena-Pardo J, Vélez-Benítez E, Contreras-Bulnes L, Bucio-Duarte JJ et al. Linfoma anaplásico de células gigantes asociado a implantes mamarios. Cir Plast. 2023;33(1):36-44. Disponible en: <https://dx.doi.org/10.35366/110922>
13. Instituto de Evaluación de Tecnologías en Salud e Investigación. Implantes Mamarios y Riesgo de Linfoma Anaplásico de Células Grandes. 2019. Disponible en: http://www.essalud.gob.pe/ieti/pdfs/farmacoytecnico/CS002_2019_implantos_mamarios.pdf

